Incyte Acquires Vega Therapeutics in $1.25B Deal

Incyte (NASDAQ: INCY) has agreed to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, for $1.25 billion upfront, with potential additional payments of up to $750 million based on sales milestones.

By Preeti Singh, SA News Editor · Seeking Alpha · June 8, 2026, 11:12 UTC

Incyte Acquires Vega Therapeutics in $1.25B Deal

Tickers: $INCY

Topics: Biotech Mergers Pharmaceuticals

Read the full article at Seeking Alpha

More World news

Allstate Announces Quarterly Dividend of $1.08 Per Share Seeking Alpha · November 12, 2026, 18:01 UTC
Pinnacle Bankshares Increases Quarterly Dividend to $0.35 Per Share Seeking Alpha · November 12, 2026, 18:02 UTC
Avidbank Reports Third Quarter 2026 Earnings Growth Driven by Core Deposits and C&I Lending Motley Fool · November 12, 2026, 18:00 UTC
Equinor Raises Production Guidance and Establishes Share Buyback Framework Motley Fool · November 12, 2026, 18:00 UTC
Flex Announces Strategic Spin-off of Cloud and Power Infrastructure Segment into Axiom Motley Fool · November 12, 2026, 18:00 UTC
Extreme Networks Raises Fiscal 2027 Revenue Guidance Amid Strong SaaS Growth and Large Enterprise Bookings Motley Fool · November 12, 2026, 18:00 UTC
Federal Reserve to Designate October 2027 Meeting as Nonvoting Strategic Session CNBC · November 12, 2026, 17:48 UTC
Pelagos Insurance Capital Reports Mixed Q3 2026 Results with Revenue Beat and EPS Miss Seeking Alpha · November 12, 2026, 18:01 UTC
Aline Accounting Partners Secures $206 Million in Financing Led by Square Nine Capital PR Newswire · November 12, 2026, 18:00 UTC
Egan-Jones November 2026 Report Shows Soft CLO Issuance Amid Improving Credit Metrics PR Newswire · November 12, 2026, 18:00 UTC